Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/31941
Title: Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: A workshop report
Authors: Lorenz Von Seidlein
Sarah Auburn
Fe Espino
Dennis Shanks
Qin Cheng
James McCarthy
Kevin Baird
Catherine Moyes
Rosalind Howes
Didier Ménard
Germana Bancone
Ari Winasti-Satyahraha
Lasse S. Vestergaard
Justin Green
Gonzalo Domingo
Shunmay Yeung
Ric Price
Menzies School of Health Research
Gokila
Australian Army Malaria Institute
University of Queensland
Eijkman-Oxford Clinical Research Unit
University of Oxford
Institut Pasteur du Cambodge
Shoklo Malaria Research Unit
The World Health Organization Regional Office for the Western Pacific philippines
GlaxoSmithKline plc.
PATH
Mahidol University
Nuffield Department of Clinical Medicine
Keywords: Immunology and Microbiology;Medicine
Issue Date: 29-Mar-2013
Citation: Malaria Journal. Vol.12, No.1 (2013)
Abstract: The diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency is a crucial aspect in the current phases of malaria control and elimination, which will require the wider use of 8-aminoquinolines for both reducing Plasmodium falciparum transmission and achieving the radical cure of Plasmodium vivax. 8-aminoquinolines, such as primaquine, can induce severe haemolysis in G6PD-deficient individuals, potentially creating significant morbidity and undermining confidence in 8-aminoquinoline prescription. On the other hand, erring on the side of safety and excluding large numbers of people with unconfirmed G6PD deficiency from treatment with 8-aminoquinolines will diminish the impact of these drugs. Estimating the remaining G6PD enzyme activity is the most direct, accessible, and reliable assessment of the phenotype and remains the gold standard for the diagnosis of patients who could be harmed by the administration of primaquine. Genotyping seems an unambiguous technique, but its use is limited by cost and the large range of recognized G6PD genotypes. A number of enzyme activity assays diagnose G6PD deficiency, but they require a cold chain, specialized equipment, and laboratory skills. These assays are impractical for care delivery where most patients with malaria live. Improvements to the diagnosis of G6PD deficiency are required for the broader and safer use of 8-aminoquinolines to kill hypnozoites, while lower doses of primaquine may be safely used to kill gametocytes without testing. The discussions and conclusions of a workshop conducted in Incheon, Korea in May 2012 to review key knowledge gaps in G6PD deficiency are reported here. © 2013 von Seidlein et al.; licensee BioMed Central Ltd.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875345746&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/31941
ISSN: 14752875
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.